| Literature DB >> 32556086 |
Koji Yamano1, Reika Kikuchi1, Waka Kojima1,2,3, Ryota Hayashida1,2,3, Fumika Koyano1, Junko Kawawaki1, Takuji Shoda4, Yosuke Demizu4, Mikihiko Naito5, Keiji Tanaka3, Noriyuki Matsuda1.
Abstract
Damaged mitochondria are selectively eliminated in a process called mitophagy. Parkin and PINK1, proteins mutated in Parkinson's disease, amplify ubiquitin signals on damaged mitochondria with the subsequent activation of autophagic machinery. Autophagy adaptors are thought to link ubiquitinated mitochondria and autophagy through ATG8 protein binding. Here, we establish methods for inducing mitophagy by mitochondria-targeted ubiquitin chains and chemical-induced mitochondrial ubiquitination. Using these tools, we reveal that the ubiquitin signal is sufficient for mitophagy and that PINK1 and Parkin are unnecessary for autophagy activation per se. Furthermore, using phase-separated fluorescent foci, we show that the critical autophagy adaptor OPTN forms a complex with ATG9A vesicles. Disruption of OPTN-ATG9A interactions does not induce mitophagy. Therefore, in addition to binding ATG8 proteins, the critical autophagy adaptors also bind the autophagy core units that contribute to the formation of multivalent interactions in the de novo synthesis of autophagosomal membranes near ubiquitinated mitochondria.Entities:
Year: 2020 PMID: 32556086 PMCID: PMC7480101 DOI: 10.1083/jcb.201912144
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Figure 1.Mitochondria-targeted linear Ub chains induce mitophagy. (A) Schematic diagram of mitochondrial targeted linear Ub chains. T20(1–49) denotes the N-terminal 49 aa of TOMM20. G75S/G76S mutations were introduced in the C-terminus of each Ub to block cleavage. (B) Immunoblots (IB) of HeLa cells transiently expressing the indicated proteins. The full-length proteins and those with additional Ub chains are indicated by blue dots and ladders, respectively. (C) The indicated proteins were expressed using Lipofectamine LTX. Total cell lysates 30 h after transfection were immunoblotted. Quantification graphs of TOMM20, MTCO2, and actin levels are indicated on the right. Error bars represent mean ± SD of three independent experiments. (D) The indicated proteins were transiently expressed in HeLa cells. At 48 h after transfection, cells were analyzed by FACS. Representative FACS data with the percentage of cells exhibiting lysosomal positive mt-Keima are shown. (E) Quantification of the FACS-based mitophagy in D. Error bars represent mean ± SD of three independent experiments. (F) Quantification of FACS-based mitophagy in WT, ATG5 KO, or Penta KO HeLa cells expressing the indicated proteins. Error bars represent mean ± SD of three independent experiments. (G) OMM-2Ub WT or K0 were transiently expressed in Penta KO HeLa cells with stable expression of each 3FLAG-autophagy adaptor. At 24 h after transfection, cells were immunostained. Scale bars, 10 µm; insets, 2 µm. (H) Quantification of FACS-based mitophagy using cells in G. Error bars represent mean ± SD of three independent experiments. (I) Quantification of FACS-based mitophagy in WT and PINK1 KO HeLa cells expressing the indicated proteins with or without 6 h of AO treatment. Error bars represent mean ± SD of three independent experiments. n.s., not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure S1.Ectopic mitochondria-targeted linear Ub chains induce mitophagy. (A) Mitochondrial localization of linear Ub chains. The indicated OMM-Ub proteins were transiently expressed in HeLa cells. The cells were immunostained with anti-HA and anti-TOMM20 antibodies. Scale bars, 10 µm. (B) Cytosolic YFP, OMM-2Ub K0, and OMM-6Ub K0 were transiently expressed in WT, ATG5 KO, or Penta KO HeLa cells stably expressing mt-Keima. At 48 h after transfection, the cells were analyzed by FACS. Representative FACS data (mt-Keima 561/488-nm ratio) with the percentage of cells exhibiting lysosomal positive mt-Keima are shown. (C) OMM-2Ub K0 was transiently expressed in Penta KO HeLa cells with stable expressions of each 3FLAG-autophagy adaptor and mt-Keima. At 48 h after transfection, the cells were analyzed by FACS. Representative FACS data (mt-Keima 561/488-nm ratio) with the percentage of cells exhibiting lysosomal positive mt-Keima are shown. (D) Cytosolic YFP and the indicated OMM-Ub proteins were transiently expressed in WT and PINK1 KO HeLa cells stably expressing mt-Keima. At 42 h after transfection, the cells were treated with or without AO for 6 h and then analyzed by FACS. Representative FACS data with the percentage of cells exhibiting lysosomal positive mt-Keima are shown.
Figure 2.SNIPER-induced mitophagy independent of PINK1 function. (A) Chemical structure of SNIPER(CRABP)-11 and schematic diagram of CRABP-II ubiquitination. (B) Schematic diagram of the CRABP-II (CII) fusion with HK1 and TOMM20 (T20). (C) Immunoblots of HT1080 cells stably expressing the indicated proteins. The full-length CRABP-II–fused proteins are indicated by the blue dots. (D) HT1080 cells stably expressing mt-Keima and the indicated proteins were immunostained. Scale bars, 10 µm. (E) Immunoblots of HT1080 cells stably expressing the indicated CRABP-II proteins following treatment with or without SNIPER(CRABP)-11 for 9 h. The full-length CRABP-II-fused proteins are indicated by the blue dots. (F) Live-cell confocal microscopy imaging of HT1080 cells in D treated with or without SNIPER(CRABP)-11 for 9 h. mt-Keima (561) signals denote mitochondria in lysosomes. Scale bars, 10 µm; insets, 2 µm. (G) HT1080 cells stably expressing mt-Keima and the indicated proteins were treated with or without SNIPER(CRABP)-11 for 9 h. Bafilomycin A1 (Baf) was added 3 h before FACS analysis. Representative FACS data with the percentage of cells exhibiting lysosomal positive mt-Keima are shown. (H) Quantification of FACS-based mitophagy in G. Error bars represent mean ± SD of three independent experiments. (I) HT1080 cells stably expressing GFP-Parkin were treated with control or PINK1 siRNA. GFP-Parkin translocation to the mitochondria was induced by 3hr treatment with valinomycin. The percentage of cells with Parkin translocation was quantified. Error bars represent mean ± SD, with >100 cells counted in each of three independent experiments. (J) HT1080 cells in G treated with control or PINK1 siRNA were treated with SNIPER(CRABP)-11 for 9 h and then analyzed by FACS. Representative FACS data with the percentage of cells exhibiting lysosomal positive mt-Keima are shown. (K) Quantification of the FACS-based mitophagy in J. Error bars represent mean ± SD of three independent experiments. n.s., not significant; ***, P < 0.001.
Figure S2.Validation of PINK1 knockdown in HT1080. (A) HT1080 cells were treated with control or PINK1 siRNAs for 48 h were then treated with valinomycin for 3 h. Total cell lysates were immunoblotted with anti-PINK1 and anti-actin antibodies. The asterisk denotes nonspecific bands. (B) HT1080 cells stably expressing GFP-Parkin treated with control or PINK1 siRNA for 48 h were then treated with valinomycin for 3 h. The cells were immunostained with anti-TOMM20 antibody. Scale bars, 10 µm.
Figure 3.Heterogeneous mitochondrial localization of OPTN and NDP52 during Parkin-mediated mitophagy. (A) Immunoblots of HeLa cells stably expressing untagged Parkin with or without 3FLAG-tagged autophagy adaptors (OPTN, NDP52, p62, and NBR1) following valinomycin treatment for 3 h. 3FLAG-tagged autophagy adaptors and those with ubiquitination are indicated by the blue and red dots, respectively. I and II denote unmodified and lipidated LC3B, respectively. ~Ub1 and ~Ub2 denote ubiquitinated forms of TOMM20. (B) HeLa cells in A were treated with valinomycin for 3 h and then immunostained. (C) The cells prepared in B were immunostained with anti-FLAG and anti-p62 antibodies. (D) HeLa cells stably expressing untagged Parkin were treated with valinomycin for 3 h and then immunostained. (E) The cells prepared in B were immunostained with anti-FLAG and anti-LC3B antibodies. Magnified images in B–E are shown. Scale bars, 10 µm; insets, 2 µm.
Figure 4.Incorporation of ATG8 family proteins into phase-separated fluorescent foci composed of autophagy adaptors and linear Ub chains. (A) Schematic diagram for generating phase-separated fluorescent foci (Fluoppi foci). The direct autophagy adaptor interactant will be incorporated into the Fluoppi foci, and the autophagosomal membrane formation will occur near the Fluoppi foci. (B) HeLa cells transiently expressing hAG-tagged autophagy adaptors and HA-Ash-6Ub were immunostained. Scale bars, 20 µm. (C) Immunoblots of cells in (B). The full-length of hAG-tagged proteins and HA-Ash–tagged proteins are indicated by blue dots, and ubiquitinated HA-Ash-6Ub are indicated by the red dots. (D) Immunoblots of ATG5 KO HeLa cells with or without stable expression of the indicated 3FLAG-ATG8 proteins. Blue dots indicate the unmodified 3FLAG-ATG8 proteins. (E) Immunoblots of WT and ATG5 KO HeLa cells stably expressing 3FLAG-LC3B. Blue and red dots indicate the unmodified and lipidated 3FLAG-LC3B, respectively. (F) Representative microscopic images of ATG8 incorporation into Fluoppi foci. Scale bars, 10 µm. (G) Efficiency of 3FLAG-ATG8 incorporation into the Fluoppi foci. Error bars represent mean ± SD, with 50 Fluoppi foci quantified in two independent experiments.
Figure S3.Incorporation of ATG8 proteins into the Fluoppi foci of autophagy adaptors. HA-Ash-6Ub– and hAG-tagged autophagy adaptors (OPTN, OPTN(S177D), NDP52, p62, or NBR1) were transiently expressed in ATG5 KO HeLa cells stably expressing 3FLAG-tagged LC3A, LC3B, LC3C, GABARAP (GABA), GABARAPL1 (L1), or GABARAPL2 (L2). The cells were immunostained with anti-FLAG and anti-HA antibodies. Scale bars, 10 µm.
Figure 5.OPTN Fluoppi foci contain ATG9A vesicles. (A) HeLa cells expressing hAG-OPTN and HA-Ash-6Ub were immunostained. For the detection of TBK1 and ATG14, HeLa cells stably expressing the 3FLAG-tagged version were used. White arrowheads indicate autophagy proteins recruited in close proximity to the Fluoppi foci. (B) Penta KO cells expressing hAG-tagged autophagy adaptors and HA-Ash-6Ub were immunostained. (C) Efficiency of ATG9A incorporation into the Fluoppi foci in B. Error bars represent mean ± SD, with 50 Fluoppi foci quantified in two independent experiments. (D) Immunoblots confirming KO of FIP200, ATG9A, and ATG5. I and II denote unmodified and lipidated LC3B, respectively. (E) WT, FIP200, and ATG5KO KO HeLa cells expressing hAG-OPTN and HA-Ash-6Ub were immunostained. (F) Efficiency of ATG9A incorporation into OPTN Fluoppi foci in E. Error bars represent mean ± SD with 50 Fluoppi foci quantified in two independent experiments. Magnified images are shown in A, B, and E. Scale bars, 10 µm; insets, 2 µm. n.s., not significant; ***, P < 0.001.
Figure S4.OPTN and NDP52 Fluoppi foci contain ATG9A and ATG13, respectively. (A) HA-Ash-6Ub– and hAG-tagged OPTN or NDP52 were transiently expressed in Penta KO HeLa cells. The cells were immunostained with anti-HA and anti-ATG9A or anti-ATG13 antibodies. Scale bars, 10 µm; insets, 2 µm. (B) HA-Ash-6Ub and hAG alone or hAG-tagged autophagy adaptors were transiently expressed in ATG9A KO HeLa cells. The cells were immunostained with anti-HA and anti-ATG13 antibodies. Scale bars, 10 µm; insets, 2 µm.
Figure 6.OPTN–ATG9A interaction depends on the leucine zipper domain, but not TBK1 activity or Ub binding. (A) Schematic diagram of the OPTN domain architecture and hAG-tagged OPTN mutants. CC, coiled-coil domains; LZ, leucine zipper; ZF, zinc finger. A summary of ATG9A and TBK1 incorporation into OPTN Fluoppi foci is shown in the rightmost panel. (B) Representative microscopic images of ATG9A incorporation into OPTN Fluoppi foci. (C) HeLa cells expressing hAG-OPTN and HA-Ash-6Ub were treated with DMSO or BX-795 for 15 h and immunostained with an anti-ATG9A antibody. (D) Efficiency of ATG9A incorporation into Fluoppi foci in C. Error bars represent mean ± SD, with 50 Fluoppi foci quantified in two independent experiments. (E) HeLa cells expressing hAG-OPTN and HA-Ash-6Ub were treated with DMSO or BX-795 for 15 h and immunostained with an anti-TBK1 (pS172) antibody. (F) Efficiency of TBK1 activation in the Fluoppi foci in E. Error bars represent mean ± SD, with 50 Fluoppi foci quantified in two independent experiments. (G) HeLa cells transiently expressing 3FLAG-hAG-OPTN and HA-Ash-6Ub were subjected to DSP cross-linking and solubilization with 1% NP-40 and immunoprecipitated with an anti-FLAG antibody. Immunoblots consisted of 5% of input and bound fractions. Red arrowheads denote oligomeric protein bands likely generated by the cross-linking. LDH was used for a negative control. (H) Immunoblots of HCT116 WT and TBK1−/− cell lysates. (I) WT and TBK1−/− HCT116 cells expressing hAG-OPTN and HA-Ash-6Ub were immunostained. (J) Efficiency of ATG9A incorporation into OPTN Fluoppi foci in I. Error bars represent mean ± SD, with 50 Fluoppi foci quantified in two independent experiments. (K) Schematic of the FRB-FKBP system for chemically inducing the recruitment of OPTN onto mitochondria. (L) HeLa cells transiently expressing OPTN-2FKBP-HA (WT and 4LA) and FRB-FIS1-TM were treated with DMSO or the A/C heterodimerizer for 3 h and then immunostained. (M) Quantification of ATG9A recruitment to mitochondria in L. Error bars represent mean ± SD, with >100 cells counted in each of three independent experiments. Scale bars, 10 µm (B, C, E, I, and L). n.s., not significant; ***, P < 0.001.
Figure S5.Incorporation of ATG9A into the Fluoppi foci produced by OPTN mutants. (A, D, and G) The indicated hAG-tagged OPTN mutants were transiently expressed in HeLa cells with HA-Ash-6Ub and then immunostained. The merged images of hAG-OPTN (green) and ATG9A immunostained (red) are shown. Scale bars, 10 µm. (B, E, and H) Efficiency of ATG9A incorporation into the mutant OPTN Fluoppi foci was quantified. Error bars represent mean ± SD, with 50 Fluoppi foci quantified in two independent experiments. Statistical differences were determined by a student’s t test (n.s., not significant; ***, P < 0.001). (C, F, and I) Total cell lysates from HeLa cells transiently expressing the indicated hAG-tagged OPTN mutants and HA-Ash-6Ub were immunoblotted. hAG-OPTN and ubiquitinated HA-Ash-6Ub are indicated by the blue dots and red arrowheads, respectively.
Figure 7.OPTN–ATG9A interaction is critical for efficient mitophagy. (A) Penta KO HeLa cells stably expressing YFP-Parkin and mt-Keima with or without the indicated 3FLAG-OPTN were treated with AO and analyzed by FACS. Representative FACS plots with the mt-Keima 561/488-nm ratio are indicated. (B) Quantification of FACS-based mitophagy in A. Error bars represent mean ± SD in three independent experiments. (C) Quantification of GFP-Parkin translocation to mitochondria in Penta KO HeLa cells with or without the indicated 3FLAG-OPTN after treatment for 3 h with AO. Error bars represent mean ± SD, with >100 cells counted in each of three independent experiments. (D) Immunoblots of Penta KO cells stably expressing untagged Parkin with or without the indicated 3FLAG-OPTN following AO treatment. (E) Penta KO HeLa cells stably expressing untagged Parkin and the indicated 3FLAG-OPTN or NDP52 were treated with valinomycin for 3 h and then immunostained. HSP60 was used as a mitochondrial marker. Scale bars, 10 µm; insets, 2 µm. (F) Quantification of ATG9A recruitment to mitochondria in cells in E. Error bars represent mean ± SD, with 50 Fluoppi foci quantified in two independent experiments. (G) HeLa cells stably expressing untagged Parkin and the indicated 3FLAG-OPTN were treated with valinomycin for 3 h and then immunostained. Line scan plots of the fluorescent signals in the merged images (indicated by the white arrows) are shown in the lower panel. Scale bars, 10 µm; insets, 2 µm. (H) Quantification of cells with either a heterogeneous or a homogeneous OPTN distribution on mitochondria after treatment with valinomycin for 3 h. Representative images are shown in the upper panel. Error bars represent mean ± SD, with >100 cells counted in each of three independent experiments. Scale bars, 10 µm. ***, P < 0.001.
Reagents and cell lines used in this study
| Reagent or resource | Source | Identifier |
|---|---|---|
| Antimycin A | Sigma-Aldrich | Catalog number A8674 |
| Oligomycin | Calbiochem | Catalog number 495455-10MGCN |
| Valinomycin | Sigma-Aldrich | Catalog number V0627 |
| A/C heterodimerizer | Clontech | Catalog number 635057 |
| Q-VD-OPH | SM Biochemicals | Catalog number SMPH001 |
| Bafilomycin A1 | Calbiochem | Catalog number 196000 |
| SNIPER(CRABP)-11 | This study | N/A |
| DMEM | Sigma-Aldrich | Catalog number D5796 |
| McCoy’s 5A | Gibco | Catalog number 16600-082 |
| FBS | Biowest | Catalog number S1820 |
| MEM nonessential amino acids solution | Gibco | Catalog number 11140-050 |
| Sodium pyruvate | Gibco | Catalog number 11360-070 |
| Penicillin–Streptomycin–Glutamine | Gibco | Catalog number 10378-016 |
| GlutaMAX supplement | Gibco | Catalog number 35050-061 |
| Hepes | Gibco | Catalog number 15630-080 |
| Opti-MEM | Gibco | Catalog number 31985-070 |
| Trypsin-EDTA (0.25%) | Gibco | Catalog number 25200-056 |
| Puromycin | Sigma-Aldrich | Catalog number P8833 |
| G418 | Sigma-Aldrich | Catalog number G8168-10ML |
| Hygromycin B | Invitrogen | Catalog number 10687010 |
| EF1-hspCas9-H1-gRNA linearized SmartNuclease vector | System Biosciences | Catalog number CAS900A-1 |
| FuGENE6 | Promega | Catalog number E269A |
| Lipofectamine LTX | Invitrogen | Catalog number 15338100 |
| Lipofectamine RNAiMAX | Invitrogen | Catalog number 13778150 |
| Polybrene | Sigma-Aldrich | Catalog number H9268 |
| Dithiothreitol | Roche | Catalog number 10708984001 |
| CHAPS | Sigma-Aldrich | Catalog number C3023 |
| NP-40 | Nacalai Tesque | Catalog number 25223-75 |
| cOmplete, EDTA-free protease inhibitor cocktail | Roche | Catalog number 11873580001 |
| PhosSTOP, phosphatase inhibitor cocktail | Roche | Catalog number 04906845001 |
| MLN-7243 (E1 inhibitor) | Active Biochem | Catalog number A-1384 |
| BX-795 (TBK1 inhibitor) | Abcam | Catalog number ab142016 |
| NEM | Wako Pure Chemical | Catalog number 058-02061 |
| DDDDK-tagged Protein PURIFICATION GEL | MBL | Catalog number 3329 |
| DSP | Thermo Fisher Scientific | Catalog number 22585 |
| 4% PFA solution | Wako Pure Chemical | Catalog number 163-20145 |
| Gelatin | Sigma-Aldrich | Catalog number G9391 |
| Triton X-100 | MP Biomedicals | Catalog number 807426 |
| Digitonin | Wako Pure Chemical | Catalog number 043-21371 |
| Tween 20 | Nacalai Tesque | Catalog number 35624-15 |
| NuPAGE 4–12% Bis-Tris gel | Invitrogen | Catalog number NP0323BOX |
| NuPAGE MOPS SDS running buffer | Invitrogen | Catalog number NP0001 |
| NuPAGE MOPS SDS running buffer | Invitrogen | Catalog number NP0002 |
| Difco skim milk | BD Biosciences | Catalog number 232100 |
| BSA (fatty acid free) | Sigma-Aldrich | Catalog number A8806 |
| Phusion high-fidelity DNA polymerase | Thermo Fisher Scientific | Catalog number F-530L |
| DNA ligation kit | TaKaRa | Catalog number 6023 |
| Western Lightning Plus-ECL | PerkinElmer | Catalog number NEL105001EA |
| ECL Prime Western blotting detection reagents | GE Healthcare | Catalog number RPN2232 |
| HeLa (corresponds to WT for PINK1 KO HeLa) | ||
| PINK1 KO HeLa | ||
| HeLa (corresponds to WT for FIP200, ATG5, ATG9A, Penta KO HeLa) | ATCC | CCL-2,2 |
| FIP200 KO HeLa | ||
| ATG5 KO HeLa | ||
| ATG9A KO HeLa | ||
| Penta (OPTN/NDP52/TAX1BP1/p62/NBR1) KO HeLa | ||
| HEK293T | ATCC | CRL-3216 |
| HT1080 | ||
| HCT116 | ||
| TBK1−/− HCT116 | This study | |
Antibodies used in this study
| Reagent or resource | Source | Identifier |
|---|---|---|
| Mouse monoclonal anti-HA (TANA2) | MBL | Catalog number M180-3, RRID:AB_10951811 |
| Rabbit polyclonal anti-TOMM20 (FL-145) | Santa Cruz Biotechnology | Catalog number sc-11415, RRID:AB_2207533 |
| Mouse monoclonal anti-MTCO2 (12C4F12) | Abcam | Catalog number Ab110258 |
| Mouse monoclonal anti-actin (C4) | Merck Millipore | Catalog number MAB1501R, RRID:AB_2223041 |
| Mouse monoclonal anti-DDDDK (FLA-1) | MBL | Catalog number M185-3L, RRID:AB_11123930 |
| Rabbit polyclonal anti-LC3B | Sigma-Aldrich | Catalog number L7543, RRID:AB_796155 |
| Guinea pig polyclonal anti-p62 | MBL | Catalog number PM066, RRID:AB_10952738 |
| Rabbit polyclonal anti-LC3B for immunofluorescence | MBL | Catalog number PM036, RRID:AB_2274121 |
| Mouse monoclonal anti-multi Ub (FK2) | MBL | Catalog number D058-3, RRID:AB_592937 |
| Rabbit monoclonal anti-Ub, Lys48-specific (Apu2) | Merck Millipore | Catalog number 05-1307, RRID:AB_1587578 |
| Rabbit monoclonal anti-Ub, Lys63-specific (Apu3) | Merck Millipore | Catalog number 05-1308, RRID:AB_1587580 |
| Mouse monoclonal anti-TOMM22 (1C9-2) | Sigma-Aldrich | Catalog number T6319, RRID:AB_261724 |
| Rabbit polyclonal anti-Azami-Green | MBL | Catalog number PM011M |
| rabbit polyclonal anti-TBK1 | Cell Signaling Technology | Catalog number 3013S, RRID:AB_2199749 |
| Rabbit monoclonal anti-phospho TBK1 (S172; D52C2) | Cell Signaling Technology | Catalog number 5483, RRID:AB_10693472 |
| Rat monoclonal anti-HA (3F10) | Roche | Catalog number 11867423001, RRID:AB_390918 |
| Rabbit polyclonal anti-DDDDK | MBL | Catalog number PM020, RRID:AB_591224 |
| Rabbit monoclonal anti-LDH (EP1566Y) | Abcam | Catalog number ab52488, RRID:AB_2134961 |
| Rabbit monoclonal anti-ATG13 (E1Y9V) | Cell Signaling Technology | Catalog number 13468S, RRID:AB_2797419 |
| Rabbit polyclonal anti-WIPI2 | Sigma-Aldrich | Catalog number SAB4200400 |
| rabbit polyclonal anti-ATG16L1 | MBL | Catalog number PM040, RRID:AB_1278757 |
| Rabbit monoclonal anti-ATG9A (EPR2450(2)) | Abcam | Catalog number ab108338, RRID:AB_10863880 |
| Rabbit monoclonal anti-FIP200 (D10D11) | Cell Signaling Technology | Catalog number 12436S, RRID:AB_2797913 |
| Rabbit polyclonal anti-OPTN | Proteintech | Catalog number 10837-1-AP, RRID:AB_2156665 |
| Rabbit monoclonal anti-NDP52 (D1E4A) | Cell Signaling Technology | Catalog number 60732, RRID:AB_2732810 |
| Mouse monoclonal anti-TOMM20 (F-10) | Santa Cruz Biotechnology | Catalog number sc-17764, RRID:AB_628381 |
| Mouse monoclonal anti-MFN2 (6A8) | Abcam | Catalog number ab56889, RRID:AB_2142629 |
| Mouse monoclonal anti-PDHA1 (8D10E6) | Abcam | Catalog number ab110334, RRID:AB_10866116 |
| Mouse monoclonal anti-PINK1 (38CT18.7) | LSBio | Catalog number LS-C96472, RRID:AB_10559463 |
| Goat polyclonal anti-HSP60 (N-20) | Santa Cruz Biotechnology | Catalog number sc-1052, RRID:AB_631683 |
| Goat anti-rabbit IgG Alexa Fluor 488 conjugated | Invitrogen | Catalog number A-11034 |
| Goat anti-rabbit IgG Alexa Fluor 568 conjugated | Invitrogen | Catalog number A-11036 |
| Goat anti-mouse IgG Alexa Fluor 488 conjugated | Invitrogen | Catalog number A-11029 |
| Goat anti-mouse IgG Alexa Fluor 568 conjugated | Invitrogen | Catalog number A-11031 |
| Goat anti-mouse IgG Alexa Fluor 647 conjugated | Invitrogen | Catalog number A-21236 |
| Goat anti-rat IgG Alexa Fluor 488 conjugated | Invitrogen | Catalog number A-11006 |
| Goat anti-rat IgG Alexa Fluor 568 conjugated | Invitrogen | Catalog number A-11077 |
| Goat anti-rat IgG Alexa Fluor 647 conjugated | Invitrogen | Catalog number A-21247 |
| Goat anti-guinea pig IgG Alexa Fluor 568 conjugated | Invitrogen | Catalog number A-11075 |
| Donkey anti-mouse IgG Alexa Fluor 488 conjugated | Abcam | Catalog number ab150105 |
| Donkey anti-rabbit IgG Alexa Fluor 568 conjugated | Abcam | Catalog number ab175470 |
| Donkey anti-goat IgG Alexa Fluor 647 conjugated | Invitrogen | Catalog number A-21447 |
| Goat Anti-rabbit IgG horseradish peroxidase-linked | Jackson ImmunoResearch | Catalog number 111-035-144 |
| Anti-mouse IgG horseradish peroxidase-linked | Promega | Catalog number W402B |
Plasmid DNAs and siRNA used in this study
| Reagent or resource | Source |
|---|---|
| Plasmid DNA | |
| pMXs-puro retroviral vector | Cell Biolabs Inc. (RTV-012) |
| pBABE-puro retroviral vector | Addgene (#1764) |
| pcDNA3.1(+) | Invitrogen (V79020) |
| pBluescriptII SK(-) | Stratagene |
| pMXs-puro_YFP | This study |
| pMXs-puro_3FLAG-TEV | This study |
| pMXs-puro_3HA-TEV | This study |
| pMXs-puro_TEV-3FLAG | This study |
| pMXs-puro_TEV-3HA | This study |
| pBABE-puro_3FLAG-TEV | This study |
| pBABE-puro_3HA-TEV | This study |
| pBABE-puro_TEV-3FLAG | This study |
| pBABE-puro_TEV-3HA | This study |
| pcDNA3.1(+)_3FLAG-TEV | This study |
| pcDNA3.1(+)_3HA-TEV | This study |
| pcDNA3.1(+)_TEV-3FLAG | This study |
| pcDNA3.1(+)_TEV-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-2Ub(WT)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-2Ub(K48R)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-2Ub(K0)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-4Ub(WT)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-4Ub(K48R)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-4Ub(K0)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-6Ub(WT)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-6Ub(K48R)-3HA | This study |
| pcDNA3.1(+)_T20(1-49)-YFP-6Ub(K0)-3HA | This study |
| pMXs-puro_3FLAG-OPTN | This study |
| pMXs-puro_3FLAG-NDP52 | This study |
| pMXs-puro_3FLAG-p62 | This study |
| pMXs-puro_3FLAG-NBR1 | This study |
| pAsh-MCL | MBL (AM-8011M) |
| pHA-Ash-MCL | This study |
| pHA-Ash_6Ub | This study |
| pHA-Ash_6Ub(K0) | This study |
| phAG-MCL | MBL (AM-8011M) |
| phAG_OPTN | This study |
| phAG_OPTN (S177D) | This study |
| phAG_NDP52 | This study |
| phAG_p62 | This study |
| phAG_NBR1 | This study |
| pEYFP-C1 | Clontech (6006-1) |
| pUMVC (Gag-Pol) | Gift from Chunxin Wang |
| pCMV-VSV-G (VSV-G) | Gift from Chunxin Wang |
| pCHAC/EYFP-LC3B-IRES-MCS2 | |
| pMXs-puro_3FLAG-LC3A | This study |
| pMXs-puro_3FLAG-LC3B | This study |
| pMXs-puro_3FLAG-LC3C | This study |
| pMXs-puro_3FLAG-GABARAP | This study |
| pMXs-puro_3FLAG-GABARAPL1 | This study |
| pMXs-puro_3FLAG-GABARAPL2 | This study |
| pWZL Neo Myr Flag TBK1 | Addgene (#20648) |
| pMXs-puro_3FLAG-TBK1 | This study |
| pMXS-IP GFP-Atg14 | Addgene (#38264) |
| pMXs-puro_3FLAG-ATG14 | This study |
| phAG_OPTN(S473E) | This study |
| phAG_OPTN(128-577, S473E) | This study |
| phAG_OPTN(150-577, S473E) | This study |
| phAG_OPTN(170-577, S473E) | This study |
| phAG_OPTN(190-577, S473E) | This study |
| phAG_OPTN(210-577, S473E) | This study |
| phAG_OPTN(301-577, S473E) | This study |
| phAG_OPTN(401-577, S473E) | This study |
| phAG_OPTN(1-530, S473E) | This study |
| phAG_OPTN(128-5A-132, S473E) | This study |
| phAG_OPTN(133-5A-137, S473E) | This study |
| phAG_OPTN(138-5A-142, S473E) | This study |
| phAG_OPTN(143-5A-147, S473E) | This study |
| phAG_OPTN(148-5A-152, S473E) | This study |
| phAG_OPTN(L143A, S473E) | This study |
| phAG_OPTN(L150A, S473E) | This study |
| phAG_OPTN(L157A, S473E) | This study |
| phAG_OPTN(L164A, S473E) | This study |
| phAG_OPTN(4LA, S473E) | This study |
| phAG_OPTN(M44Q/L54Q, S473E) | This study |
| pcDNA3.1(+)_3FLAG-hAG-OPTN(S473E) | This study |
| pcDNA3.1(+)_3FLAG-hAG-OPTN(M44Q/L54Q, S473E) | This study |
| pcDNA3.1(+)_3FLAG-hAG-OPTN(4LA, S473E) | This study |
| pEF1-hspCas9-H1-gRNA TBK1-ex6-3 | This study |
| pUC57-Amp_TBK1-ex6 donor | This study |
| pUC57-Amp_TBK1-ex6 loxP-NeoR-donor | This study |
| pUC57-Amp_TBK1-ex6 loxP-HygroR-donor | This study |
| FRB-Fis1 | |
| PINK1Δ110-YFP-FKBP | |
| pOPTN(1-444)-2FKBP-HA | This study |
| pOPTN(1-444, 4LA)-2FKBP-HA | This study |
| pBMNz-YFP-Parkin | |
| pRetroQ-mt-Keima | Gift from Chunxin Wang |
| pBABE-puro_Untag-Parkin | This study |
| pMXs-puro_GFP-Parkin | |
| pMXs-puro_3FLAG-OPTN(4LA) | This study |
| pMXs-puro_3FLAG-OPTN(F178A) | This study |
| pMXs-puro_3FLAG-OPTN(4LA, F178A) | This study |
| p3xFLAG-CMV-10_CRABP-II | |
| pMXs-puro_3HA-TEV-CRABP-II | This study |
| pMXs-puro_CRABP-II-TEV-3HA | This study |
| pcDNA3.1-HA_HK1 | |
| pMXs-puro_HK1-CRABP-II-TEV-3HA | This study |
| pMXs-puro_TOMM20-CRABP-II-TEV-3HA | This study |
| Oligonucleotides | |
| siRNA PINK1 (GGGUCAGCACGUUCAGUUAdTdT) | Sigma-Aldrich |